Market research
ONC.TO Oncolytics Biotech Inc
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 143M
- P/E ratio
- Not available
- Analyst target
- 5.125
- Dividend yield
- Not available
- Beta
- 1.48
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA6823108759
- Market cap
- 143M
- P/E ratio
- Not available
- Analyst target
- 5.125
- Dividend yield
- Not available
- Beta
- 1.48
About
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ONC.TO discussion.
5 years, 5 months ago
Oncolytics Biotech Inc is currently in a long term downtrend where the price is trading 5.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Oncolytics Biotech Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 51.9% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 20.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Oncolytics Biotech Inc gets an overall score of 3/5.